Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0782
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2616
    -0.0006 (-0.05%)
     
  • USD/JPY

    151.3400
    -0.0320 (-0.02%)
     
  • Bitcoin USD

    69,754.66
    -770.67 (-1.09%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Spiros Segalas Comments on Danaher

- By Holly LaFon

Danaher (NYSE:DHR), a new position added during the quarter, is a diversified conglomerate whose subsidiaries design, manufacture, and market products and offer services geared to worldwide professional, medical and dental, industrial, and commercial markets. In February, the company announced that it is buying GE Life Sciences' biopharmaceutical business, a leading provider of instruments, consumables, and software that support the research, discovery, process development, and manufacturing workflows of biopharmaceutical drugs. In our view, the business is attractive for its recurring revenue and distinct and scarce life sciences and diagnostics capabilities. We believe that Danaher is likely to establish a dominant position in the bioproduction/manufacturing industry.


From Spiros Segalas (Trades, Portfolio)' first-quarter 2019 Harbor Capital Appreciation Fund commentary.
This article first appeared on GuruFocus.


Advertisement